|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ettinger DS, Akerley W, Borghaei H, Chang
AC, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK,
Govindan R, et al: Non-small cell lung cancer. J Natl Compr Canc
Netw. 10:1236–1271. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Torre LA, Siegel RL and Jemal A: Lung
Cancer statistics. Adv Exp Med Biol. 893:1–19. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cobb MH, Hepler JE, Cheng M and Robbins D:
The mitogen-activated protein kinases, ERK1 and ERK2. Semin Cancer
Biol. 5:261–268. 1994.PubMed/NCBI
|
|
6
|
Ren G, Liu X, Mao X, Zhang Y, Stankiewicz
E, Hylands L, Song R, Berney DM, Clark J, Cooper C and Lu YJ:
Identification of frequent BRAF copy number gain and alterations of
RAF genes in Chinese prostate cancer. Genes Chromosomes Cancer.
51:1014–1023. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Slattery ML, Lundgreen A and Wolff RK: MAP
kinase genes and colon and rectal cancer. Carcinogenesis.
33:2398–2408. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Borovski T, Vellinga TT, Laoukili J, Santo
EE, Fatrai S, van Schelven S, Verheem A, Marvin DL, Ubink I, Borel
Rinkes IHM and Kranenburg O: Inhibition of RAF1 kinase activity
restores apicobasal polarity and impairs tumour growth in human
colorectal cancer. Gut. 66:1106–1115. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang F, Jiang C, Sun Q, Yan F, Wang L, Fu
Z, Liu T and Hu F: miR-195 is a key regulator of raf1 in thyroid
cancer. Onco Targets Ther. 8:3021–3028. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wellbrock C, Karasarides M and Marais R:
The RAF proteins take centre stage. Nat Rev Mol Cell Biol.
5:875–885. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
McKay MM and Morrison DK: Integrating
signals from RTKs to ERK/MAPK. Oncogene. 26:3113–3121. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
McCubrey JA, Steelman LS, Chappell WH,
Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M,
Tafuri A, et al: Roles of the Raf/MEK/ERK pathway in cell growth,
malignant transformation and drug resistance. Biochim Biophys Acta.
1773:1263–1284. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Steelman LS, Chappell WH, Abrams SL, Kempf
RC, Long J, Laidler P, Mijatovic S, Maksimovic-Ivanic D, Stivala F,
Mazzarino MC, et al: Roles of the Raf/MEK/ERK and
PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity
to therapy-implications for cancer and aging. Aging (Albany NY).
3:192–222. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hwang YH, Choi JY, Kim S, Chung ES, Kim T,
Koh SS, Lee B, Bae SH, Kim J and Park YM: Over-expression of
c-raf-1 proto-oncogene in liver cirrhosis and hepatocellular
carcinoma. Hepatol Res. 29:113–121. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kyriakis JM, App H, Zhang XF, Banerjee P,
Brautigan DL, Rapp UR and Avruch J: Raf-1 activates MAP
kinase-kinase. Nature. 358:417–421. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xu ZH, Hang JB, Hu JA and Gao BL:
RAF1-MEK1-ERK/AKT axis may confer NSCLC cell lines resistance to
erlotinib. Int J Clin Exp Pathol. 6:1493–504. 2013.PubMed/NCBI
|
|
17
|
Kordi-Tamandani DM, Saberi E, Jamali S and
Ladiz MA: ERK and RAF1 gene: Analysis of methylation and expression
profiles in patients with oral squamous cell carcinoma. Br J Biomed
Sci. 71:100–103. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen L, Wang Q, Wang GD, Wang HS, Huang Y,
Liu XM and Cai XH: Mir-16 inhibits cell proliferation by targeting
IGF1R and the Raf1-MEK1/2-ERK1/2 pathway in osteosarcoma. FEBS
Lett. 587:1366–1372. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Petti C, Picco G, Martelli ML, Trisolini
E, Bucci E, Perera T, Isella C and Medico E: Truncated RAF kinases
drive resistance to MET inhibition in MET-addicted cancer cells.
Oncotarget. 6:221–233. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xiao Z, Ding N, Xiao G, Wang S, Wu Y and
Tang L: Reversal of multidrug resistance by gefitinib via RAF1/ERK
pathway in pancreatic cancer cell line. Anat Rec (Hoboken).
295:2122–2128. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Robinson D, Van Allen EM, Wu YM, Schultz
N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC
and Attard G: Integrative clinical genomics of advanced prostate
cancer. Cell. 161:1215–1228. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lawson AR, Tatevossian RG, Phipps KP,
Picker SR, Michalski A, Sheer D, Jacques TS and Forshew T: RAF gene
fusions are specific to pilocytic astrocytoma in a broad paediatric
brain tumour cohort. Acta Neuropathol. 120:271–273. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Brennan DF, Dar AC, Hertz NT, Chao WC,
Burlingame AL, Shokat KM and Barford D: A Raf-induced allosteric
transition of KSR stimulates phosphorylation of MEK. Nature.
472:366–369. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li P, Wood K, Mamon H, Haser W and Roberts
T: Raf-1: A kinase currently without a cause but not lacking in
effects. Cell. 64:479–482. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rohrbeck A, Müller VS and Borlak J:
Molecular characterization of lung dysplasia induced by c-Raf-1.
PLoS One. 4:e56372009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li X, Stevens PD, Liu J, Yang H, Wang W,
Wang C, Zeng Z, Schmidt MD, Yang M, Lee EY and Gao T: PHLPP is a
negative regulator of RAF1, which reduces colorectal cancer cell
motility and prevents tumor progression in mice. Gastroenterology.
146:1301–1312. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
He W, Wu Y, Tang X, Xia Y, He G, Min Z, Li
C, Xiong S, Shi Z, Lu Y and Yuan Z: HDAC inhibitors suppress
c-Jun/Fra-1-mediated proliferation through transcriptionally
downregulating MKK7 and Raf1 in neuroblastoma cells. Oncotarget.
7:6727–6747. 2016.PubMed/NCBI
|
|
28
|
Chai J, Wang S, Han D, Dong W, Xie C and
Guo H: MicroRNA-455 inhibits proliferation and invasion of
colorectal cancer by targeting RAF proto-oncogene
serine/threonine-protein kinase. Tumour Biol. 36:1313–1321. 2015.
View Article : Google Scholar : PubMed/NCBI
|
